AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 231 min read$CTSO

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents (CTSO) announced it regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company's stock closed at or above this price for 10 consecutive trading sessions. CytoSorbents is also working to meet other Nasdaq listing requirements by December 28, 2026. The company aims to drive sales, achieve cash flow breakeven, and advance regulatory approvals for its products.

Original reporting
prnewswire.com
Published Sep 23, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CTSOBullishLow
01

Why it matters

Regaining Nasdaq $1 bid price compliance removes a delisting threat, supporting short‑term stability.

02

Market read

Primary relevance is to CTSO shareholders; broader market effect is limited.

03

What to watch

Future capital market listing requirements and cash‑flow breakeven targets remain uncertain.

Relevance 6/10Novelty 6/10Timing: today

Background

CytoSorbents (NASDAQ: CTSO) is a medical‑device company focused on blood purification technologies.

Company-level read

Ticker impact

$CTSOBullishMedium confidence
Context

CytoSorbents announced it regained Nasdaq minimum bid price compliance, a new listing status update.

Expected impact

Potential modest upside as delisting risk is removed.

Evidence & confidence

The news removes a negative catalyst; investors often reward compliance restoration.

Market effects

Sector

May slightly improve sentiment for small-cap biotech/medical device sector.

Regional

Limited to U.S. market where CTSO trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

If compliance is short-lived, price could fall once the next Nasdaq requirement is missed.

Key entities

  • company
    CytoSorbents Corporation

    Issuer of the compliance news.

  • regulator
    Nasdaq Listing Qualifications Department

    Entity that confirmed compliance.

Read at source← All news

Related articles

AUG 14
$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

fool.com6 min
AUG 6
$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

SEC EDGAR 8-K6 min
JUN 2
$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

fool.com6 min